Key snapshot
Novartis AG options volume climbed to 26,086 contracts by 10:10 a.m., with puts narrowly ahead of calls - 13,209 versus 12,877. Among the active trades, a single large block in a September call contract and a long-dated put spread stand out for their size and potential market impact.
Options pulse: volume and structure
The overall options flow is elevated and broadly balanced between calls and puts. The near parity in call and put volume suggests traders are not placing one-way directional wagers; instead, many are building positions that reflect an expectation of heightened price movement, or are protecting existing exposures.
Two trades in particular define the session. First, a large September call - specifically the Sept. 18, 2026 CHF130 call - recorded 4,334 contracts traded and currently shows open interest of 9,743. This single transaction represents a substantial proportion of open contracts at that strike and is consistent with either a large new bullish position or a sizeable adjustment of an existing position.
Second, a March 19, 2027 CHF110/CHF140 put spread totaling 4,000 contracts is clearly a hedging construct. The spread involves buying the CHF110 put while selling the CHF140 put, a structure that provides protection against a decline to CHF110 while offsetting some of the cost by taking on the sold put leg. This trade profile implies a desire for tail-risk protection without expecting a complete collapse in the stock.
Other notable flows
- The October CHF128 put traded 3,250 contracts, an indication of concentrated bearish protection in the nearer-term October expiry.
- A mixed September position pairing a CHF135 call with a CHF120 put moved 1,800 contracts, showing participants are bracing for potential moves in both directions.
What the strike clusters imply
Activity clusters around the CHF130-CHF135 calls and CHF120-CHF128 puts point to a contested price band where traders expect the stock to test or react over the coming weeks. Large open interest at these strikes increases the likelihood that sharp moves will prompt follow-on hedging or unwind activity from market makers, which can magnify volatility.
Long-dated hedges, such as the March 2027 put spread, reveal at least one sizeable participant is concerned about tail risk well into next year. By selling the CHF140 put while buying the CHF110 put, that player caps their downside protection cost while limiting the position's payoff range.
Interpreting the broader picture
The combination of nearly equal call and put volumes and the prevalence of spread strategies suggests uncertainty in direction rather than conviction. The trades read more like institutional risk management - protecting gains or insulating portfolios from shocks - than outright one-sided speculative bets.
Given the timing and strike distribution, expiries in September and October are likely focal points. If the underlying stock moves toward any of the heavily traded strikes, dynamic hedging by market makers could accelerate that move - a gamma squeeze effect that can amplify price swings as dealers adjust their delta hedges.
Takeaway
The current options landscape around Novartis AG points to increased price variability ahead. Elevated, balanced volume and large structured trades - both near-term and long-dated - indicate institutional positioning for potential catalysts or market shifts, rather than a consensus directional bet.